Nexalis Therapeutics (ASX:NX1) Debt-to-Equity: -0.78 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nexalis Therapeutics Debt-to-Equity?

Nexalis Therapeutics ASX:NX1 Debt-to-Equity is -0.78 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 954 Biotechnology companies, Nexalis Therapeutics ranks worse than 104821.7% on this metric.

Nexalis Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.43 Mil. Nexalis Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.32 Mil. Nexalis Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$-0.95 Mil. Nexalis Therapeutics's debt to equity for the quarter that ended in Dec. 2025 was -0.78.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nexalis Therapeutics's Debt-to-Equity or its related term are showing as below:

ASX:NX1' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.78   Med: -0.53   Max: 0.84
Current: -0.78

During the past 10 years, the highest Debt-to-Equity Ratio of Nexalis Therapeutics was 0.84. The lowest was -0.78. And the median was -0.53.

ASX:NX1's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs ASX:NX1: -0.78

Nexalis Therapeutics  (ASX:NX1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nexalis Therapeutics Debt-to-Equity Related Terms

Nexalis Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Nexalis Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalis Therapeutics Debt-to-Equity Chart

Nexalis Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.84 -0.53 -0.78

Nexalis Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 -6.14 -0.53 -0.38 -0.78

ASX:NX1 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison

For the Biotechnology subindustry, Nexalis Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nexalis Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nexalis Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nexalis Therapeutics's Debt-to-Equity falls into.


Nexalis Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nexalis Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.426 + 0.315) / -0.951
=-0.78

Nexalis Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.426 + 0.315) / -0.951
=-0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.78 mean?
Nexalis Therapeutics (ASX:NX1) has a Debt-to-Equity of -0.78 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nexalis Therapeutics and its competitors. According to the industry distribution chart, Nexalis Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry.
Is Nexalis Therapeutics' Debt-to-Equity too high?
Nexalis Therapeutics' current Debt-to-Equity is -0.78. Based on the distribution chart, Nexalis Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nexalis Therapeutics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nexalis Therapeutics ranks #999999 out of 954 companies for Debt-to-Equity. This places Nexalis Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nexalis Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexalis Therapeutics's current Debt-to-Equity is -0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current Debt-to-Equity of -0.78. The current Debt-to-Equity is -0.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current Debt-to-Equity is -0.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexalis Therapeutics Business Description

Address 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.